دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Clinical Variables Associated With Statural Growth in Pediatric Crohn’s Disease Differ by Sex (The Growth Study)
Neera Gupta, MD, MAS, Robert H Lustig, MD, MSL, Howard Andrews, PhD, Ranjana Gokhale, MD, Alka Goyal, MD
doi : 10.1093/ibd/izaa220
Volume 27, Issue 6, June 2021, Pages 751–759
Statural growth impairment is more common in male patients with Crohn’s disease (CD). We identified clinical variables associated with height z score differences by sex in children participating in the Growth Study, a prospective multicenter longitudinal study examining sex differences in growth impairment in pediatric CD.
IBD Systems Biology Is Here to Stay
Claudio Fiocchi, MD, Dimitrios Iliopoulos, PhD
doi : 10.1093/ibd/izaa343
Volume 27, Issue 6, June 2021, Pages 760–770
Systems biology is a rapidly advancing field of science that allows us to look into disease mechanisms, patient diagnosis and stratification, and drug development in a completely new light. It is based on the utilization of unbiased computational systems free of the traditional experimental approaches based on personal choices of what is important and what select experiments should be performed to obtain the expected results.
Variations in Health Care Utilization Patterns Among Inflammatory Bowel Disease Patients at Risk for High Medical Service Utilization Enrolled in High Deductible Health Plans
Jeffrey A Berinstein, MD, MSc, Shirley A Cohen-Mekelburg, MD, MSc, Calen A Steiner, MD, MS, Megan McLeod, MD, Mohamed Noureldin, MBBS, MS
doi : 10.1093/ibd/izaa179
Volume 27, Issue 6, June 2021, Pages 771–778
High-deductible health plans (HDHPs) are increasing in prevalence as a cost control device for slowing health care cost growth by reducing nonessential medical service utilization. High cost-sharing associated with HDHPs can lead to significant financial distress and worse disease outcomes. We hypothesize that chronic disease patients are delaying or foregoing necessary medical care due to health care costs
Yield of Random Biopsies During Colonoscopies in Inflammatory Bowel Disease Patients Undergoing Dysplasia Surveillance
Anne B Hu, MD, Kristin E Burke, MD, MPH, Bharati Kochar, MD, MSCR, Ashwin N Ananthakrishnan, MD, MPH
doi : 10.1093/ibd/izaa205
Volume 27, Issue 6, June 2021, Pages 779–786
The development of chromoendoscopy (CE) and high definition endoscopy (HDE) has improved detection of subtle colonic dysplasia in patients with inflammatory bowel diseases (IBDs). The role of random biopsies for dysplasia surveillance is unclear.
Finding a Needle in the Haystack? Defining the Role of Random Biopsies in IBD Dysplasia Surveillance
Waseem Ahmed, MD, Dana J Lukin, MD, PhD
doi : 10.1093/ibd/izaa206
Volume 27, Issue 6, June 2021, Pages 787–790
High Levels of Psychological Resilience Associated With Less Disease Activity, Better Quality of Life, and Fewer Surgeries in Inflammatory Bowel Disease
Priya Sehgal, MD, MPH, Ryan C Ungaro, MD, MS, Carol Foltz, PhD, Brian Iacoviello, PhD, Marla C Dubinsky, MD
doi : 10.1093/ibd/izaa196
Volume 27, Issue 6, June 2021, Pages 791–796
Stress and depression are risk factors for inflammatory bowel disease (IBD) exacerbations. It is unknown if resilience, or one’s ability to recover from adversity, impacts disease course. The aim of this study was to examine the association between resilience and IBD disease activity, quality of life (QoL), and IBD-related surgeries.
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management
Bruce E Sands, MD, Jean-Frédéric Colombel, MD, Christina Ha, MD, Michel Farnier, MD, Alessandro Armuzzi, MD, PhD
doi : 10.1093/ibd/izaa227
Volume 27, Issue 6, June 2021, Pages 797–808
Patients with ulcerative colitis (UC) are at elevated risk of cardiovascular disease vs the general population, despite a lower prevalence of traditional risk factors, including hyperlipidemia. Mechanistic studies in patients with rheumatoid arthritis and psoriasis suggest that tofacitinib restores serum lipids to preinflammation levels by reversing inflammation-induced cholesterol metabolism changes. We reviewed data on lipid levels and cardiovascular events, alongside recommendations for managing lipid levels during tofacitinib treatment in patients with UC, based on up-to-date expert guidelines.
Prevalence, Predictors, and Disease Activity of Sacroiliitis Among Patients with Crohn’s Disease
Irving Levine, MD, Fardina Malik, MBBS, MS, Gabriel Castillo, MD, Brian Jaros, MD, Erin Alaia, MD
doi : 10.1093/ibd/izaa198
Volume 27, Issue 6, June 2021, Pages 809–815
Sacroiliitis is an inflammatory arthritis of the sacroiliac joints and is associated with inflammatory bowel disease (IBD). Yet, sacroiliitis often goes undiagnosed in IBD, and the clinical association between IBD disease activity and sacroiliitis is not well established. Patients with Crohn’s disease (CD) often receive magnetic resonance enterography (MRE) to assess disease activity, affording clinicians the opportunity to evaluate for the presence of sacroiliitis. We aimed to identify the prevalence and disease characteristics associated with sacroiliitis in CD patients undergoing MRE.
Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program
Gary R Lichtenstein, MD, Gerhard Rogler, MD, PhD, Matthew A Ciorba, MD, Chinyu Su, MD, Gary Chan, PharmD
doi : 10.1093/ibd/izaa199
Volume 27, Issue 6, June 2021, Pages 816–825
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Here, we performed an integrated analysis of malignancy events from the tofacitinib phase 3 UC clinical development program (excluding nonmelanoma skin cancer [NMSC]).
The IBD-F Patient Self-Assessment Scale Accurately Depicts the Level of Fatigue and Predicts a Negative Effect on the Quality of Life of Patients With IBD in Clinical Remission
Ioannis Varbobitis, MD, MSc, Georgios Kokkotis, MD, Michael Gizis, MD, Nikoletta Perlepe, MD, Efrosini Laoudi, MD
doi : 10.1093/ibd/izaa201
Volume 27, Issue 6, June 2021, Pages 826–835
Fatigue is highly prevalent among patients with inflammatory bowel disease (IBD) and may have an unfavorable impact on quality of life (QoL). The IBD-Fatigue scale (with components SCORE1 and SCORE2) is a recently developed disease-specific questionnaire. We sought to validate a Greek version of IBD-F and use it to assess the severity and characteristics of fatigue and its effect on QoL in our study population.
Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey
Charles N Bernstein, MD, Siew C Ng, MD, PhD, Rupa Banerjee, MD, Flavio Steinwurz, MD, Bo Shen, MD
doi : 10.1093/ibd/izaa202
Volume 27, Issue 6, June 2021, Pages 836–847
Persons with inflammatory bowel disease (IBD) may be particularly vulnerable to COVID-19 either because of their underlying disease or its management. Guidance has been presented on the management of persons with IBD in the time of this pandemic by different groups. We aimed to determine how gastroenterologists around the world were approaching the management of IBD.
Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn’s Disease: A Post Hoc Analysis of the IM-UNITI Trial
Emily C L Wong, John K Marshall, MD, MSc, Walter Reinisch, MD, Neeraj Narula, MD, MPH
doi : 10.1093/ibd/izaa214
Volume 27, Issue 6, June 2021, Pages 848–854
This post hoc analysis aimed to evaluate the impact of BMI on the efficacy of ustekinumab in the IM-UNITI study.
Serum IgG4 Subclass Deficiency Defines a Distinct, Commonly Encountered, Severe Inflammatory Bowel Disease Subtype
Filippos Koutroumpakis, MD, Anna Evans Phillips, MD, Dhiraj Yadav, MD, MPH, Jorge D Machicado, MD, Maaz Ahsan
doi : 10.1093/ibd/izaa230
Volume 27, Issue 6, June 2021, Pages 855–863
Immunoglobulin G subclass 4 (IgG4) is hypothesized to play an immunomodulatory role, downregulating humoral immune responses. The role of this anti-inflammatory molecule in inflammatory bowel disease (IBD) has not been fully characterized. We sought to define alterations in serum IgG4 in patients with IBD and their association with multiyear disease severity.
Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures
Carlos Taxonera, MD, PhD, Cristina Alba, MD, David Olivares, BD, Mar?a Martin, RN, Alejandro Ventero, MD
doi : 10.1093/ibd/izaa223
Volume 27, Issue 6, June 2021, Pages 864–869
The coronavirus 2019 (COVID-19) pandemic is a clinical situation that could be used as prototype for implementation of new systems of care.
Understanding the Molecular Drivers of Disease Heterogeneity in Crohn’s Disease Using Multi-omic Data Integration and Network Analysis
Padhmanand Sudhakar, PhD, Bram Verstockt, MD, PhD, Jonathan Cremer, Sare Verstockt, PhD, Jo?o Sabino, MD, PhD
doi : 10.1093/ibd/izaa281
Volume 27, Issue 6, June 2021, Pages 870–886
Crohn’s disease (CD), a form of inflammatory bowel disease (IBD), is characterized by heterogeneity along multiple clinical axes, which in turn impacts disease progression and treatment modalities. Using advanced data integration approaches and systems biology tools, we studied the contribution of CD susceptibility variants and gene expression in distinct peripheral immune cell subsets (CD14+ monocytes and CD4+ T cells) to relevant clinical traits.
Impaired IFN-?-dependent STAT3 Activation Is Associated With Dysregulation of Regulatory and Inflammatory Signaling in Monocytes of Ulcerative Colitis Patients
Friederike Cordes, MD, Eva Lenker, MD, Toni Weinhage, PhD, Lea J Spille, Dominik Bettenworth, MD
doi : 10.1093/ibd/izaa280
Volume 27, Issue 6, June 2021, Pages 887–901
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) inhibitor tofacitinib has been recently approved for the treatment of ulcerative colitis (UC) but not Crohn’s disease (CD). Systematic analysis of the JAK/STAT pathway in inflammatory bowel disease is still missing. The aim of this study was to investigate JAK/STAT activation and adjacent signaling in monocytes of patients with inflammatory bowel diseases, which are key players in inflammatory responses.
Impact of the Trophic Effects of the Secretome From a Multistrain Probiotic Preparation on the Intestinal Epithelia
Valentina Petito, MSc, PhD, Viviana Greco, MSc, PhD, Lucrezia Laterza, MD, PhD, Cristina Graziani, MSc, PhD, Caterina Fanali, MSc, PhD
doi : 10.1093/ibd/izaa298
Volume 27, Issue 6, June 2021, Pages 902–913
Probiotics are defined as live, nonpathogenic bacteria that confer health benefits beyond their nutritional value. In particular, VSL#3 exhibits demonstrated efficacy in the management of diseases characterized by an increased intestinal permeability. Our study aimed to understand how VSL#3 promotes gut health by secreting bioactive factors and identify which human pathways are modulated by secretome derived from the VSL#3 formula.
Salicylates Ameliorate Intestinal Inflammation by Activating Macrophage AMPK
Suhrid Banskota, PhD, Huaqing Wang, MS, Yun Han Kwon, MS, Jaya Gautam, PhD, Pallavi Gurung, PhD
doi : 10.1093/ibd/izaa305
Volume 27, Issue 6, June 2021, Pages 914–926
Inflammatory bowel diseases are the most common chronic intestinal inflammatory conditions, and their incidence has shown a dramatic increase in recent decades.
Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases
Mohamed Attauabi, Mirabella Zhao, MD, Flemming Bendtsen, MD, DMSci, Johan Burisch, MD, PhD
doi : 10.1093/ibd/izaa167
Volume 27, Issue 6, June 2021, Pages 927–939
Patients with inflammatory bowel diseases (IBDs) are at risk of developing a variety of other immune-mediated inflammatory diseases (IMIDs). The influence of co-occurring IMIDs on the disease course of IBD remains unknown. The aim of this study was therefore to conduct a systematic review and meta-analysis of the impact of IMIDs on phenotypic presentation and outcome in patients with IBD.
Review of Societal Recommendations Regarding Management of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic
Laurie B Grossberg, MD, Randall S Pellish, MD, Adam S Cheifetz, MD, Joseph D Feuerstein, MD
doi : 10.1093/ibd/izaa174
Volume 27, Issue 6, June 2021, Pages 940–946
Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Austin Lin, MD, Hannah Roth, MD, Adjoa Anyane-Yeboa, MD, David T Rubin, MD, Sonali Paul, MD, MS
doi : 10.1093/ibd/izaa189
Volume 27, Issue 6, June 2021, Pages 947–955
Nonalcoholic fatty liver disease (NAFLD) is a significant public health burden, with up to 30% of the US population affected. The prevalence of NAFLD among inflammatory bowel disease (IBD) patients is unknown. Understanding risk factors for NAFLD in IBD patients has implications in the treatment of these patients. The purpose of this study was to determine the prevalence of NAFLD among IBD patients and to identify risk factors associated with NAFLD development.
Combining Therapies in Inflammatory Bowel Disease: End of the Line or a New Era?
Ciaran Judge, MRCPI, Reza Saeidi, MD, Kathleen Sugrue, RANP, Louise Rabbitt, MRCPI, MSc, Aine Keogh, MSc, RANP
doi : 10.1093/ibd/izab028
Volume 27, Issue 6, June 2021, Pages 956–959
Reducing the Spread of Internet Misinformation in IBD: Ethics and Responsibility
Jacob A Kurowski, MD, Meenakshi Bewtra, MD, MPH, PhD, Eric Kodish, MD, Bret Lashner, MD
doi : 10.1093/ibd/izaa335
Volume 27, Issue 6, June 2021, Pages 960–962
Corrigendum to: Impact of the Trophic Effects of the Secretome From a Multistrain Probiotic Preparation on the Intestinal Epithelia
doi : 10.1093/ibd/izab049
Volume 27, Issue 6, June 2021, Page e79
How Can We Predict Who Would Benefit From a Small-Bowel Capsule Endoscopy When Staging Crohn Disease?
Alexander R Robertson, MBChB, MRCP, Ian D Arnott, BSc, MBChB, FCRP, MD
doi : 10.1093/ibd/izab013
Volume 27, Issue 6, June 2021, Pages e67–e68
Real-World Effectiveness of Ustekinumab Dose Intensification in Crohn’s Disease
Ashish Srinivasan, MBBS (Hons), FRACP, Daniel van Langenberg, MBBS, PhD, FRACP, Peter De Cruz, MBBS, PhD, FRACP
doi : 10.1093/ibd/izab018
Volume 27, Issue 6, June 2021, Page e69
Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All
Rahul S Dalal, MD, Jessica R Allegretti, MD, MPH
doi : 10.1093/ibd/izab019
Volume 27, Issue 6, June 2021, Page e70
Cerebral Venous Thrombosis in a Child With Very-Early-Onset IBD
Francesco Graziano, MD, Martina Busè, MD, Nicola Cassata, MD, Michele Citrano, MD
doi : 10.1093/ibd/izab050
Volume 27, Issue 6, June 2021, Pages e71–e73
Leukocytoclastic Vasculitis in Cutaneous Crohn Disease in the Setting of COVID-19
Najib Nassani, MD, MSc, Nadera Sweiss, MD, John Thomas Berry, DO, Clarence Calhoun, II, Anne Polick, MD
doi : 10.1093/ibd/izab045
Volume 27, Issue 6, June 2021, Pages e74–e75
Onset of Suspected Ulcerative Colitis After Treatment With Tocilizumab in Patient With Celiac Disease and Juvenile Idiopathic Arthritis
Raffaele Borghini, MD, PhD, Mariavittoria Vescovo, MD, Carla Giordano, MD, PhD, Giuseppe Donato, MD, Antonio Picarelli, MD
doi : 10.1093/ibd/izab036
Volume 27, Issue 6, June 2021, Pages e76–e78
